[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Peking University Third Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":653},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,176,0,25,[9,46,73,102,132,162,185,208,233,263,283,313,334,359,381,412,429,453,479,503,526,551,574,598,620],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100512089","real-time-continuous-glucose-monitoring-system-in-t2dm-with-pregnacy-100512089",false,"NCT05947916","Real Time Continuous Glucose Monitoring System in T2DM With Pregnacy","Effect of Real Time Continuous Glucose Monitoring System on Management of Women With Type 2 Diabetes Mellitus During Pregnancy in a Multidisciplinary Comprehensive System","Inclusion Criteria:\n\n* A clear history of type 2 diabetes, or a history of type 2 diabetes diagnosed in early pregnancy\n* Singleton gestation at 4-26 weeks, with substandard glycemic control (i.e., fasting glucose \\> 5.3 mmol\u002FL, and or 1 hour postprandial glucose \\> 7.8 mmol\u002FL, and or 2 hours postprandial glucose \\> 6.7 mmol\u002FL) after lifestyle intervention ± basal insulin therapy, as assessed by the endocrinology department. Patients who need insulin regimen with basal plus meal or insulin pump regimen.\n* Patients are willing and committed to establish and follow up in the obstetrics and gynecology departments of Peking University Third Hospital, Haidian District Hospital and Yanqing District Hospital during pregnancy, and are willing to provide information on obstetric examination and perinatal medical records if they are transferred to the hospital for special reasons for follow-up or delivery.\n* Voluntarily participate in the study, examine and follow up according to this project and sign informed consent.\n* Able to pass the screening period Adherence evaluation\n\nExclusion Criteria:\n\n* Patients with type 1 diabetes, specific type of diabetes or gestational diabetes\n* Pregnancy with severe comorbidities or diabetic complications for which obstetrics does not recommend continuation of pregnancy, including but not limited to the following: proliferative retinopathy, chronic kidney disease (eGFR less than 60 mL\u002Fmin\u002F1.73± massive proteinuria), known coronary and cerebrovascular disease, autoimmune system disease and receiving exogenous glucocorticoids or immunosuppressive therapy.\n* Patients who have been hospitalized for psychiatric treatment within 6 months prior to enrollment or are still on psychiatric medications.\n* Patients who have received other interventional studies.","FEMALE","18 Years","40 Years",{"count":21,"type":22},240,"ESTIMATED","INTERVENTIONAL",[25],"NA","The prevalence of type 2 diabetes mellitus (T2DM) in women of childbearing age is increasing rapidly, and low glucose compliance leads to an increased risk of adverse pregnancy outcomes for mothers and infants during pregnancy in women with T2DM. Real-time continuous glucose monitoring (CGM) is an important tool for glucose monitoring and patient education, as it can continuously record blood glucose throughout the day and provide real-time feedback on high and low blood glucose levels. This is a multicenter, open-label, randomized controlled clinical study to investigate the efficacy, safety, and maternal and infant pregnancy outcomes of using real-time CGM monitoring compared with conventional self-monitoring of blood glucose (SMBG) on the basis of multidisciplinary management in pregnant women with T2DM. One hundred and twenty pregnant women with T2DM in early pregnancy who were enrolled in intensive insulin therapy were randomly divided into the real-time CGM group and the conventional SMBG group. The real-time CGM intervention group wore real-time CGM for more than 50% of the pregnancy in addition to regular SMBG; the control group only performed regular SMBG. Both groups wore Medtronic iPro 2 for 3 days in early, mid and late pregnancy, and the time in the target range of blood glucose (TIR) was recorded in a blinded manner. Primary outcome: differences in TIR between the two groups of pregnant women in early, mid, and late pregnancy. Secondary outcomes included differences in glycated hemoglobin, hypoglycemia, insulin dose before delivery, pregnancy weight gain, and maternal and infant pregnancy outcomes.",[28,29,30,31,32],"Type2diabetes","Pregnancy Related","Continuous Glucose Monitoring","Time in Range","Pregnancy Outcome","RECRUITING","2026-06-30",{"date":36,"type":37},"2026-07-02","ACTUAL",{"date":39,"type":37},"2024-01-30",{"date":41,"type":22},"2026-12-31",{"name":43,"class":44},"Peking University Third Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":57,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":72,"locationsCount":45},"100643905","the-impact-of-preoperative-quantitative-flow-reserve-qfr-on-early-postoperative-radial-artery-graft-outcomes-in-coronary-artery-bypass-grafting-100643905","NCT07669987","The Impact of Preoperative Quantitative Flow Reserve (QFR) on Early Postoperative Radial Artery Graft Outcomes in Coronary Artery Bypass Grafting","QFR-RADIAL","Inclusion Criteria:\n\n* Patients aged 18 to 80 years.\n* Patients whose angina pectoris significantly affects daily life and work, and for whom conservative medical treatment is ineffective, requiring coronary artery bypass grafting (CABG).\n* Preoperative coronary angiography data are available for quantitative flow ratio (QFR) analysis.\n* Patients with severe stenosis, defined as greater than 70% stenosis, in the three main coronary artery branches, including the left anterior descending artery, circumflex artery, and right coronary artery, with or without left main coronary artery stenosis greater than 50%.\n\nExclusion Criteria:\n\n* Patients who cannot tolerate CABG due to comorbidities or complications.\n* Patients requiring urgent CABG or percutaneous coronary intervention (PCI).\n* Patients with significant congestive heart failure or hemodynamic instability.\n* Patients with a history of previous CABG or PCI within the past 6 months.\n* Patients who have experienced a stroke within the past 6 months.\n* Patients requiring concurrent cardiac procedures, such as valve surgery, maze surgery, radiofrequency ablation, or pacemaker implantation.\n* Patients with allergies to contrast agents or antiplatelet medications, or with contraindications to antiplatelet medications due to bleeding risks.\n* Patients with a significant history of bleeding, marked leukopenia, neutropenia, thrombocytopenia, anemia, or bleeding diathesis.\n* Patients currently participating in other prospective clinical studies.\n* Patients who are unwilling to participate in this study.","ALL","80 Years",{"count":56,"type":22},110,"12 Months","OBSERVATIONAL","The goal of this observational study is to learn about the long-term effects of Quantitative Flow Reserve (QFR) assessment in patients undergoing Coronary Artery Bypass Grafting (CABG). The main question it aims to answer is:\n\nDoes preoperative QFR measurement improve graft outcomes and reduce major adverse cardiac and cerebrovascular events (MACE) in patients undergoing CABG?\n\nParticipants who are scheduled for CABG and have undergone preoperative QFR assessment will be followed for one year post-surgery. They will provide data on graft patency and report any occurrences of MACE through regular follow-up visits and questionnaires about their health status.",[61,62,63],"Quantitative Flow Reserve","Minimally Invasive Coronary Surgery","Radial Artery",[61,65,63],"minimally invasive coronary surgery","2026-06-22",{"date":68,"type":37},"2026-06-25",{"date":70,"type":37},"2023-01-01",{"date":41,"type":22},{"name":43,"class":44},{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":53,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100644720","high-frequency-short-course-extracorporeal-shock-wave-therapy-for-partial-rotator-cuff-tears-study-protocol-for-a-multicenter-randomized-controlled-trial-100644720","NCT07673055","High-frequency Short-course Extracorporeal Shock Wave Therapy for Partial Rotator Cuff Tears: Study Protocol for a Multicenter, Randomized, Controlled Trial","Inclusion Criteria:\n\n* Age 30-70 years, male or female\n* MRI- or high-resolution ultrasound-confirmed partial-thickness rotator cuff tear (predominantly supraspinatus) or small full-thickness tear without retraction or displacement\n* Shoulder pain duration ≥3 months with Visual Analog Scale (VAS) score ≥4 (0-10 scale)\n* Willing and able to provide written informed consent and comply with the study protocol\n\nExclusion Criteria:\n\n* Large or massive full-thickness rotator cuff tear, tear with Grade II retraction or greater, or presence of a greater tuberosity bone cyst\n* Severe muscle fatty infiltration (Goutallier grade ≥3) on MRI\n* Uncontrolled diabetes mellitus (HbA1c \\>7.5%), hypothyroidism, or heavy smoking (≥20 pack-years)\n* Received local injection therapy (e.g., corticosteroids, platelet-rich plasma) to the affected shoulder within 4 weeks prior to enrollment\n* Concurrent shoulder pathologies including glenohumeral osteoarthritis, adhesive capsulitis (frozen shoulder), or shoulder instability\n* Systemic diseases (e.g., rheumatoid arthritis), bleeding disorders, or coagulopathy\n* Pregnancy or lactation\n* Contraindications to ESWT (e.g., cardiac pacemaker, malignancy at treatment site)\n* Inability to complete treatment or follow-up schedule",true,"30 Years","70 Years",{"count":83,"type":22},300,[25],"This is a multicenter, randomized controlled clinical study exploring three different extracorporeal shock wave therapy (ESWT) regimens for patients with partial rotator cuff tears, a common cause of chronic shoulder pain and limited movement. Traditional ESWT uses a once-weekly treatment schedule over 7 weeks, which takes a long time and leads to low patient compliance. This study aims to test two new high-frequency, short-course ESWT protocols, compare their pain relief, shoulder function improvement, tendon healing effect, safety and treatment adherence with the conventional regimen, and finally establish a more efficient, patient-friendly standardized treatment plan for clinical use. A total of 300 eligible participants will be recruited from 10 top-tier hospitals across China and followed up for 12 months after treatment.",[87],"Partial Rotator Cuff Tears (PRCTs)",[89,90,91,92,93],"Partial rotator cuff tears","Extracorporeal shock wave therapy","High-frequency short-course therapy","Shoulder pain","Treatment adherence","NOT_YET_RECRUITING",{"date":96,"type":37},"2026-06-29",{"date":98,"type":22},"2027-01-01",{"date":100,"type":22},"2030-01-01",{"name":43,"class":44},{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":17,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":113,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},"100643215","zishen-yutai-pill-for-patients-with-recurrent-implantation-failure-100643215","NCT07641088","Zishen Yutai Pill for Patients With Recurrent Implantation Failure","Zishen Yutai Pill for Patients With Recurrent Implantation Failure: a Randomized, Double-blind, Parallel-group, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Meet the diagnostic criteria for recurrent implantation failure;\n2. Aged between 20-40 years old (inclusive) when oocytes were retrieved, and \\\u003C43 at enrollment;\n3. Have at least 1 good-quality embryo for transfer;\n4. Intend to undergo frozen-thawed embryo transfer;\n5. Voluntary participation and signed informed consent.\n\nExclusion Criteria:\n\n1. Concomitant unresolved intrauterine lesions (e.g., intrauterine adhesions grade III-IV, endometrial polyps ≥1 cm, acute endometritis), endometriosis (ASRM stage ≥III), or adenomyosis (uterine volume ≥8 weeks of gestation) that affect embryo implantation;\n2. Intend to undergo FET after preimplantation genetic testing (PGT), including aneuploidy screening (PGT-A), monogenic disease testing (PGT-M), chromosomal structural rearrangement testing (PGT-SR);\n3. Thin endometrium (\\\u003C7 mm) before enrollment;\n4. Concomitant severe genital malformations or genital neoplasms;\n5. Contraindications to estrogen and progestogen (e.g., history of breast cancer);\n6. Presence of medical contraindications to assisted reproductive technology, including that either partner has a severe psychiatric disorder, acute genitourinary tract infection, sexually transmitted disease, serious deleterious habit (e.g., drug abuse), or teratogenic exposure to radiation, toxic agent or medication that still under effect; or genetic diseases specified in the Law of the People's Republic of China on Maternal and Infant Health Care for which childbearing and PGT are contraindicated; or severe somatic diseases incompatible with pregnancy; or chromosomal abnormalities;\n7. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>1.5 × the upper limit of normal (ULN), or serum creatinine (Scr) \\> ULN;\n8. Presence of poorly controlled severe systemic diseases, including cardiovascular, digestive, endocrine, and autoimmune diseases (e.g., antiphospholipid syndrome, Sjögren's syndrome, systemic lupus erythematosus, rheumatoid arthritis);\n9. Use of traditional Chinese medicines with similar functions and indications to ZYP within 1 month before screening that may affect treatment efficacy. Chinese patent medicines such as Tiaojing Cuyun Pills, Kuntai Capsules, Peikun Pills, Qilin Pills, Jinfeng Pills, Gushen Antai Pills, and Chinese herbal decoctions containing Cuscutae Semen, Dipsaci Radix, Taxilli Herba, and Asini Corii Colla with kidney-tonifying and spleen-strengthening effects;\n10. Allergy to any component of the study drugs;\n11. Participated in another interventional trials within 1 month prior to enrollment;\n12. Deemed unsuitable for this study by the investigator.","20 Years","43 Years",{"count":112,"type":22},878,[25],"The goal of this clinical trial is to evaluate the efficacy of Zishen Yutai Pill (ZYP) on pregnancy outcomes following embryo transfer and its safety in patients with recurrent implantation failure. The main question it aims to answer is whether ZYP can improve live birth rate in participant's frozen embryo transfer (FET) cycles.\n\nResearchers will compare ZYP to a placebo (a look-alike substance with similar characteristics to ZYP) to see if it works to improve pregnancy outcomes.\n\nParticipants will:\n\n1. Start to receive ZYP or placebo (5g per time, 3 times daily) within the first 5 days of their initial menstrual cycle, and will undergo FET in the following cycle. The medication will be taken without interruption till the day of pregnancy test (2 weeks after embryo transfer). Patients with positive results in β-HCG test will continue to take the drug until clinical pregnancy confirmation by ultrasound three weeks later. For those with a negative β-HCG result, the intervention will be stopped.\n2. Baseline visit will be conducted on days 2-4 of the participant's first menstrual cycle. Subsequent clinic visits will follow the standard protocol for FET cycle, as outlined below:\n\nVisit 1 (days 2-4 of the second menstrual cycle); Visit 2 (day of ovulation or day of endometrial transformation); Visit 3 (day of embryo transfer); Visit 4 (2 weeks after embryo transfer); Visit 5 (5 weeks after embryo transfer). Follow-up is scheduled at 10 weeks after embryo transfer (Visit 6) and after delivery (Visit 7), and these can be conducted remotely.",[116],"Recurrent Implantation Failure",[118,119,120,121,122],"traditional Chinese medicine","Zishen Yutai pill","recurrent implantation failure","frozen-thawed embryo transfer","randomized controlled trial","2026-06-10",{"date":125,"type":37},"2026-06-11",{"date":127,"type":22},"2026-07-01",{"date":129,"type":22},"2029-12-31",{"name":43,"class":44},13,{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":54,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":45},"100642575","phase-2-ev--toripalimab-vs-gc-as-neoadjuvant-therapy-in-locally-advancedhigh-risk-mibc-100642575","NCT07647289","EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced\u002FHigh-Risk MIBC","A Phase II, Two-arm, Open-label, Multicenter, Randomized Controlled Clinical Study Evaluating the Safety and Efficacy of Enfortumab Vedotin Combined With Toripalimab Versus Gemcitabine Combined With Cisplatin in the Neoadjuvant Treatment of Patients With Locally Advanced\u002FHigh-risk Muscle-invasive Bladder Cancer","Inclusion Criteria:\n\n* Voluntarily agree to participate in the study and sign the informed consent form (ICF).\n* Age ≥ 18 and ≤ 80 years at the time of signing the ICF.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Histologically confirmed muscle-invasive urothelial carcinoma of the bladder, with variant histology components comprising \\\u003C 50%.\n* Radiographically confirmed non-metastatic urothelial carcinoma (M0). Clinical stage must be locally advanced or possess high-risk features, including at least one of the following: clinical stage cT3-T4aNxM0, or definitive high-risk cT2 (e.g., accompanied by tumor-related hydronephrosis, lymphovascular invasion).\n* Participants must be evaluated as fit for and scheduled to undergo radical surgery, and clinically fit to tolerate cisplatin-based chemotherapy.\n* Able to provide tumor tissue samples (at least 5 unstained slides, or paraffin scrolls\u002Fblocks).\n* Expected life expectancy of at least 12 weeks.\n* Adequate organ function, defined by the following laboratory values (obtained without blood transfusion within 14 days or growth factor support within 7 days prior to testing): Absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL; Platelet count (PLT) ≥ 100 × 10\\^9\u002FL; Hemoglobin (Hb) ≥ 90 g\u002FL; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × Upper Limit of Normal (ULN); Total bilirubin (TBIL) ≤ 1.5 × ULN; International Normalized Ratio (INR) ≤ 1.5 × ULN; Creatinine clearance ≥ 60 mL\u002Fmin (calculated using the Cockcroft-Gault formula); Left ventricular ejection fraction (LVEF) ≥ 50%; QTcF interval ≤ 480 ms.\n* Female participants of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose of study treatment and must be willing to use highly effective contraception during the study and for 180 days after the last dose.\n* Male participants with female partners of childbearing potential must be surgically sterile or willing to use highly effective contraception during the study and for 180 days after the last dose.\n* Able to understand and comply with study visits, treatment plans, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n* Prior systemic anti-tumor therapy for urothelial carcinoma, including radiotherapy, chemotherapy, targeted therapy, or biological therapy (except for intravesical instillation therapy).\n* Prior treatment with PD-1\u002FPD-L1 inhibitors or antibody-drug conjugates (ADCs).\n* Active malignancies other than urothelial carcinoma within 3 years prior to the first dose, except for curatively treated malignancies (e.g., basal or squamous cell skin cancer, localized low-risk prostate cancer, papillary thyroid cancer, carcinoma in situ of the cervix, ductal carcinoma in situ of the breast).\n* Active autoimmune disease requiring systemic treatment (e.g., use of disease-modifying agents, corticosteroids, or immunosuppressants) within 2 years prior to the first dose; or received high-dose steroids (\\>10 mg\u002Fday prednisone equivalent) or other immunosuppressive medications within 14 days prior to the first dose. (Physiological replacement therapies are permitted).\n* Severe thromboembolic events or severe cardiovascular\u002Fcerebrovascular diseases within 1 year prior to the first dose, including but not limited to myocardial infarction, unstable angina, pulmonary embolism, cerebral hemorrhage, cerebral infarction, and deep vein thrombosis.\n* Major surgical procedure within 28 days prior to the first dose; or cystoscopy\u002Fureteroscopy biopsy or intravesical therapy within 7 days prior to the first dose.\n* Peripheral neuropathy ≥ Grade 2.\n* Severe dry eye syndrome, active keratitis, corneal ulcers, or conditions assessed by the investigator as increasing the risk of corneal disease and unsuitable for participation.\n* Active infections, including: Positive HBsAg with HBV-DNA copy number ≥ 500 IU\u002FmL; Positive HCV antibody with positive HCV-RNA; Positive HIV antibody; Active tuberculosis infection; Other active infections requiring systemic therapy within 7 days prior to the first dose.\n* Other severe or uncontrolled diseases, including but not limited to: Severe respiratory diseases (e.g., moderate-to-severe interstitial or obstructive pulmonary disease, severe asthma); New York Heart Association (NYHA) Class III or IV heart failure; HbA1c ≥ 8% (except for participants whose fasting blood glucose is stably controlled at ≤ 10 mmol\u002FL with medication); Poorly controlled hypertension (systolic BP ≥ 160 mmHg and\u002For diastolic BP ≥ 100 mmHg); Large pleural effusion or ascites requiring symptomatic treatment within 14 days prior to the first dose.\n* Receipt of live vaccines within 28 days prior to the first dose or plans to receive live vaccines during the study.\n* Prior allogeneic hematopoietic stem cell transplantation or solid organ transplantation.\n* Use of strong CYP3A4 inhibitors or inducers within 14 days prior to the first dose.\n* Known severe hypersensitivity or intolerance to the study drugs or any of their excipients.\n* Substance abuse or psychiatric disorders that may interfere with study compliance.\n* Any other condition that, in the opinion of the investigator, makes the participant unsuitable for the study.",{"count":140,"type":22},58,[142],"PHASE2","The purpose of this Phase II, open-label, multicenter, randomized controlled study is to evaluate the efficacy and safety of Enfortumab Vedotin in combination with Toripalimab compared to Gemcitabine plus Cisplatin. This regimen is evaluated as a neoadjuvant treatment for patients with locally advanced or high-risk muscle-invasive bladder cancer. Participants will be randomly assigned in a 1:1 ratio to one of two cohorts. Cohort A will receive Enfortumab Vedotin and Toripalimab for 3 treatment cycles. Cohort B will receive Gemcitabine and Cisplatin for 3 treatment cycles. Following the neoadjuvant treatment phase, patients will undergo radical cystectomy and pelvic lymph node dissection. The primary endpoint of the study is the 1-year Event-Free Survival (EFS) rate. Secondary endpoints include pathological downstaging rate (pDR), pathological complete response (pCR), Disease-Free Survival (DFS), Overall Survival (OS), and the assessment of adverse events. Additionally, the study will evaluate the relationship between treatment efficacy and the expression of PD-L1 and Nectin-4 in tumor tissues.",[145],"Muscle-Invasive Bladder Cancer (MIBC)",[147,148,149,150,151,152,153],"MIBC","Neoadjuvant Therapy","Enfortumab Vedotin","Toripalimab","Antibody-Drug Conjugates","Nectin-4","Urothelial Carcinoma","2026-06-09",{"date":156,"type":37},"2026-06-15",{"date":158,"type":37},"2025-04-15",{"date":160,"type":22},"2028-12",{"name":43,"class":44},{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":23,"phases":171,"briefSummary":172,"conditions":173,"keywords":176,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":184,"locationsCount":45},"100643628","efficacy-evaluation-of-intelligent-rehabilitation-programs-based-on-ai-powered-digital-rehabilitation-system-for-subacromial-impingement-syndrome-100643628","NCT07638761","Efficacy Evaluation of Intelligent Rehabilitation Programs Based on AI-Powered Digital Rehabilitation System for Subacromial Impingement Syndrome","Inclusion Criteria:① Meet the diagnostic criteria for SIS (Subacromial Impingement Syndrome), i.e., 3 or more of the following 5 signs: tenderness on the anterior or lateral aspect of the acromion; positive Neer sign; positive Hawkins-Kennedy sign; positive painful arc test; positive external rotation resistance test;\n\n* MRI shows hyperintensity indicating subacromial bursitis;\n\n  * Aged 18-60 years;\n\n    * Conscious, able to understand and cooperate with rehabilitation training, and willing to accept regular follow-up; ⑤ No shoulder surgery within the past 1 year, no other shoulder joint-related diseases, and no need for surgical intervention; ⑥ Voluntarily sign the informed consent form and commit to participating in the entire study.\n\nExclusion Criteria:① Concurrent shoulder dislocation, fracture, shoulder arthritis, calcific tendinitis, or other shoulder joint diseases;\n\n* History of shoulder surgery or current injury is an old tear (course \\>6 months without standardized treatment);\n\n  * Suffering from severe cardiovascular or cerebrovascular diseases, diabetes, rheumatoid arthritis, osteoporosis, or other systemic diseases that may affect rehabilitation outcomes;\n\n    * Cognitive impairment that prevents normal participation in rehabilitation training, or other conditions judged by the physician as making the patient unsuitable for the trial;\n\n      ⑤ Participation in other rehabilitation intervention clinical trials within the past 1 month.","60 Years",{"count":170,"type":22},93,[25],"This non-randomized controlled trial will compare the efficacy of a conventional rehabilitation program versus an AI-based digital rehabilitation system in patients with subacromial impingement syndrome (SIS).",[174,175],"Articular","Range of Motion",[177,178,179],"Subacromial Impingement Syndrome","Artificial Intelligence","Digital Rehabilitation System",{"date":123,"type":37},{"date":182,"type":22},"2026-10-14",{"date":182,"type":22},{"name":43,"class":44},{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":53,"minAge":192,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":45},"100585048","comparison-of-mbr--suture-tape-and-mbr-for-clai--a-prospective-cohort-study-100585048","NCT06897293","Comparison of MBR + Suture Tape and MBR for CLAI : A Prospective Cohort Study","Comparison of Modified Broström Repair + Suture Tape and Modified Broström Repair for Chronic Lateral Ankle Instability : A Prospective Cohort Study","Inclusion Criteria:\n\n* Clinical diagnosis of lateral ankle instability\n* Beighton score ≥4\n* Age with 18 to 60 years\n\nExclusion Criteria:\n\n* Patients with an acute or subacute ankle injury\n* Injury of the deltoid ligament\n* Alignment of lower extremity greater than 5 degrees\n* Fractures of the lower extremity\n* Stage III or IV osteoarthritis\n* Patients who refused to participate in the study","15 Years","55 Years",{"count":195,"type":22},86,"GJL is a risk factor for postoperative recurrent instability following an MBR for CLAI. Additional suture tape augmentation has been suggested to provide more strength and stability. However, the outcomes of the MBP with suture tape augmentation were unknown, which requires further exploration.",[198,199],"Ankle Sprain","Hypermobility, Joint","2026-05-18",{"date":202,"type":37},"2026-05-20",{"date":204,"type":37},"2021-06-01",{"date":206,"type":22},"2026-06-01",{"name":43,"class":44},{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":17,"minAge":109,"maxAge":19,"enrollmentInfo":216,"targetDuration":4,"studyType":23,"phases":218,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":4},"100638840","early-prevention-and-precision-management-of-female-fertility-decline-100638840","NCT07581444","Early Prevention and Precision Management of Female Fertility Decline","Development and Evaluation of a Precision Prevention Strategy for Early Female Fertility Decline Based on OvaRePred-Plus: A Multicenter Cluster Randomized Controlled Trial","OvaRePred-Plus","Inclusion Criteria:\n\n* Women aged 20-40 years\n* Diagnosed with infertility or planning assisted reproductive treatment\n* Regular menstrual cycles (21-35 days)\n* Willing to participate in a 12-week lifestyle intervention program\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Known chromosomal abnormalities or genetic disorders affecting fertility\n* History of ovarian surgery or severe ovarian damage\n* Diagnosed endocrine disorders affecting reproduction (e.g., uncontrolled thyroid disease, hyperprolactinemia)\n* Severe systemic diseases (e.g., cardiovascular, hepatic, renal diseases)\n* Current pregnancy or breastfeeding\n* Use of hormonal medications or supplements affecting ovarian function within the past 3 months\n* Participation in another clinical trial within the past 3 months",{"count":217,"type":22},384,[25],"Female fertility decline has become an important public health issue in China, with a substantial proportion of women of reproductive age experiencing reduced ovarian reserve. However, effective tools for early identification and large-scale prevention of fertility impairment in the general population are still lacking.\n\nThis study aims to develop and evaluate a precision prevention strategy for early female fertility decline based on the OvaRePred-Plus model, which integrates ovarian reserve markers, lifestyle factors, and reproductive health indicators. A multicenter, cluster randomized controlled trial will be conducted across six medical centers in China, enrolling women aged 20-40 years identified as having early signs of fertility decline.\n\nParticipants will be allocated to either an intervention group receiving a comprehensive health management program (including dietary optimization, nutritional supplementation, physical activity, and sleep improvement) or a control group receiving routine clinical care. The intervention will last for 12 weeks.\n\nThe primary outcome is the change in fertility score assessed by the OvaRePred-Plus model. Secondary outcomes include changes in ovarian reserve markers (e.g., AMH), menstrual status, ultrasound parameters, and reproductive outcomes.\n\nThis study is expected to provide evidence for a scalable and cost-effective strategy for early prevention and management of female fertility decline.",[221,222,223,224],"Female Fertility Decline","Diminished Ovarian Reserve","Reproductive Health","Infertility Prevention","2026-05-06",{"date":227,"type":37},"2026-05-12",{"date":229,"type":22},"2026-06",{"date":231,"type":22},"2026-12",{"name":43,"class":44},{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":79,"sex":53,"minAge":240,"maxAge":241,"enrollmentInfo":242,"targetDuration":4,"studyType":23,"phases":244,"briefSummary":245,"conditions":246,"keywords":251,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":45},"100633879","probiotic-intervention-on-the-development-of-allergic-diseases-in-infants-exposed-to-antibiotics-early-in-life-100633879","NCT07532421","Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life","A Study on the Impact of Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life","Inclusion Criteria:\n\n* Gestational age from 37 weeks to less than 41 weeks;\n* Birth weight between the 10th and 90th percentiles for gestational age;\n* Breastfed (exclusively breastfed after achieving stable feeding volume, with willingness to maintain exclusive breastfeeding for at least 3 months);\n* Postnatal age within 35 days; Consent to participate in this study.\n\nExclusion Criteria:\n\n* Postnatal Apgar score \\\u003C7;\n* Presence of severe congenital malformations or inherited metabolic diseases;\n* Use of probiotics by the infant or the mother within 2 weeks before enrollment.","1 Day","35 Days",{"count":243,"type":22},400,[25],"Early antibiotic exposure is an important environmental factor that disrupts the establishment of the infant gut microbiota and leads to microbial dysbiosis. Accumulating epidemiological evidence indicates that exposure to antibiotics early in life (including both prenatal and postnatal periods) is significantly associated with an increased risk of allergic diseases in childhood. As live microorganisms, probiotics hold potential as a preventive strategy against allergies due to their ability to stabilize the intestinal barrier and regulate immune balance (e.g., promoting Th1\u002FTh2 balance, inducing regulatory T cells, and increasing sIgA secretion). However, current studies have mostly focused on general or high-risk infant populations. For the specific high-risk subgroup that has already been exposed to antibiotics early in life, high-quality randomized controlled trial evidence is still lacking regarding whether probiotic intervention can effectively reduce the incidence of allergies and whether it exerts its effects by reshaping the gut microbiota and metabolites disrupted by antibiotics.\n\nThis study focuses on breastfed infants who received antibiotics during the early postnatal period (within 30 days after birth) and aims to investigate the effect of a probiotic mixture containing Bifidobacterium longum subsp. infantis R0033, Lactobacillus helveticus R0052, and Bifidobacterium bifidum R0071 on the development of allergic diseases after antibiotic exposure.",[247,248,249,250],"Antibiotic","Allergic Diseases","Infants","Probiotic",[252,253,254,255],"probiotics","infants","early postnatal antibiotic exposure","allergic diseases",{"date":257,"type":37},"2026-05-11",{"date":259,"type":22},"2026-04-17",{"date":261,"type":22},"2027-10-31",{"name":43,"class":44},{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":12,"sex":53,"minAge":269,"maxAge":270,"enrollmentInfo":271,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":272,"conditions":273,"keywords":275,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":282,"locationsCount":45},"100589955","prospective-cohort-study-on-fuzheng-yangxin-prescription-for-rapid-rehabilitation-of-patients-with-qi-yin-deficiency-syndrome-after-coronary-artery-bypass-grafting-100589955","NCT06961136","Prospective Cohort Study on Fuzheng Yangxin Prescription For Rapid Rehabilitation of Patients With Qi-Yin Deficiency Syndrome After Coronary Artery Bypass Grafting","Inclusion Criteria:\n\n* Patients who received coronary artery bypass surgery with syndrome differentiation of Qi-Yin deficiency after operation\n\nExclusion Criteria:\n\n* ① Patients allergic to Fuzheng Yangxin Fang granules\n\n  * Patients with postoperative cold and fever ③ Patients with severe postoperative hepatic and renal insufficiency ④ Other circumstances: Concurrent valvular surgery or other cardiac surgery, end-stage malignant tumor, uncontrolled infection, bleeding, progressive degenerative systemic disease, severe brain injury, multiple organ failure, other vital organ dysfunction such as severe liver impairment, severe heart failure or cardiogenic shock, inability to tolerate surgery, etc.","25 Years","85 Years",{"count":83,"type":22},"Data from the Global Burden of Disease Study 2021, recently published in the Lancet, show that ischaemic heart disease remains the first most common cause of death worldwide. Ischemic heart disease mainly refers to coronary artery stenosis or obstruction caused by coronary artery atherosclerosis leading to myocardial ischemia heart disease, called coronary heart disease. \"China Cardiovascular Health and Disease Report 2022\" mentioned that coronary heart disease is an important cardiovascular disease affecting the health of Chinese residents, and its prevalence and mortality are on the rise. Coronary artery bypass grafting (CABG) and interventional therapy (PCI) are commonly used in the treatment of coronary heart disease. CABG surgery can significantly reduce the recurrence of angina pectoris, the incidence of acute myocardial infarction and improve the survival rate of patients, the patency rate of 5 years after mammary arterial bridge can reach more than 90%. Current guidelines and various RCT studies have shown that CABG is the gold standard for revascularization in patients with complex coronary artery disease. With the increasing aging of Chinese population, there are more and more cases of complex coronary artery diseases, and CABG, as the first choice for complex coronary artery diseases, will be more and more widely used in the foreseeable future. At present, the number of coronary artery bypass surgery is on the rise, about 50,000 cases per year. Traditional Chinese medicine can play a role in preventing complications, improving the quality of life and long-term curative effect of patients after CABG. It is particularly important to actively seek the treatment of integrated Chinese and Western medicine for patients after CABG. This study aims to explore the effectiveness and safety of Fuzheng Yangxin prescription in the treatment of Qi-Yin deficiency after CABG by means of a prospective cohort study, so as to determine the efficacy of Fuzheng Yangxin prescription on the recovery after CABG. To formulate a routine program of Chinese and Western combined therapy for postoperative rehabilitation of cardiac surgery, and actively promote the technology and program, promote the transformation of intellectual property rights, etc., and contribute to the formulation of relevant guidelines.",[274],"Coronary Artery Bypass",[274,276],"Chinese herbal medicine",{"date":278,"type":37},"2026-05-08",{"date":280,"type":37},"2025-05-10",{"date":34,"type":22},{"name":43,"class":44},{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":81,"enrollmentInfo":290,"targetDuration":4,"studyType":23,"phases":292,"briefSummary":293,"conditions":294,"keywords":300,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":312},"100635403","nk-cell-therapy-for-malignant-solid-brain-tumors-100635403","NCT07552233","NK Cell Therapy for Malignant Solid Brain Tumors","NK Cell Therapy for the Treatment of Malignant Solid Brain Tumors","Inclusion Criteria:\n\n1. Male or female, age 18-70 years old (both ends included)\n2. At least one evaluable lesion with previous biopsy or pathohistologic confirmation of malignant central nervous system tumor, with imaging suggestive of continued progression or recurrence after comprehensive treatment\n3. Karnofsky Performance Status (KPS) ≥ 60%\n4. Life expectancy \\> 4 weeks, and must be able to undergo an MRI with contrast\n5. Patients who completed radiotherapy or systemic therapies (including temozolomide\u002Fbevacizumab or other agents) for at least 4 weeks prior to enrollment. All prior treatment-related toxicities should be defined as ≤ grade 1 (except for toxicities such as alopecia or leukoplakia) according to the Common Terminology Standard for Adverse Events (CTCAE 6.0)\n6. Dexamethasone dose ≤ 4 mg\u002Fday or equivalent corticosteroid dose, or no dexamethasone administered\n7. Must have adequate organ and marrow function as defined below:\n\n   * White blood cell count (WBC) ≥ 3 x 10\\^9\u002FL\n   * Absolute neutrophil count (ANC) \\> 1 x 10\\^9\u002FL\n   * Hemoglobin (Hb) ≥ 90 g\u002FL\n   * Platelet (PLT) ≥ 80×10\\^9\u002FL\n   * Albumin transaminase (ALT) \\& albumin transaminase (AST) \\\u003C 1.5 × institutional upper limit of normal (ULN)\n   * Serum creatinine (Cr) \\\u003C 1.5 x institutional ULN\n   * Total bilirubin \\\u003C 1.5 x institutional ULN\n   * PT \\& PTT ≤ 1.25 x institutional ULN\n8. No obvious hereditary diseases\n9. Normal cardiac function with left ventricular ejection fraction \\>55%\n10. No bleeding and coagulation disorders\n11. Absence of positive blood cultures for bacteria, fungus, or virus within 48-hours prior to NK cell infusion and\u002For there aren't any indications of meningitis\n12. Fertile women must have had a pregnancy test with a negative result within 7 days prior to the start of treatment, and subjects are willing to use contraception (hormonal or barrier method of birth control or abstinence) during the clinical trial and for 6 months after the last cell infusion; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately\n13. Signed, written informed consent\n\nExclusion Criteria:\n\n1. Active hepatitis B or C virus, HIV infection, or other untreated active infection\n2. Pregnant and lactating women\n3. Participants with organ failure\n4. Participants with a chronic disease requiring immunologic or hormonal therapy\n5. Participants with an allergy to immunotherapy and related cells\n6. Participants with uncontrolled intercurrent illness\n7. Participants with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n8. Participants with a history of organ transplantation or who are awaiting organ transplantation",{"count":291,"type":22},27,[25],"This is a multi-center, open-label investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, and feasibility of combined intracranial and intravenous administration of ex vivo expanded and activated natural killer (NK) cells in adult patients with malignant solid brain tumors who have failed standard treatment modalities. The primary objective is to determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of the combined NK cell therapy. Secondary objectives include preliminary assessment of anti-tumor activity as measured by progression-free survival (PFS), overall survival (OS), objective response rate (ORR) per RANO criteria, and evaluation of the immunological effects of NK cell infusion in the tumor microenvironment and peripheral blood.",[295,296,297,298,299],"Malignant Solid Brain Tumors","Glioblastoma (GBM)","Glioblastoma Multiforme (GBM)","Brain Metastasis","Malignant Meningioma",[295,301,302,303],"Immunotherapy","Natural Killer Cell","NK Cell","2026-04-20",{"date":306,"type":37},"2026-04-27",{"date":308,"type":22},"2026-04",{"date":310,"type":22},"2030-12-31",{"name":43,"class":44},4,{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":320,"enrollmentInfo":321,"targetDuration":4,"studyType":23,"phases":323,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":333,"locationsCount":45},"100510264","effects-of-preoperative-rehabilitation-on-tendon-healing-bone-mineral-density-and-cartilage-after-aclr-and-patellar-dislocation-100510264","NCT05924178","Effects of Preoperative Rehabilitation on Tendon Healing, Bone Mineral Density, and Cartilage After ACLR and Patellar Dislocation","A Study on the Effect of Exercise Rehabilitation on Bone Mineral Density, Reconstruction Ligament Tendon Bone Healing and Cartilage After ACL Rupture and Patellar Dislocation","Inclusion Criteria:\n\n1. Age 18\\~40 years old, diagnosed ACL rupture or Patellar Dislocation by MRI;\n2. The first unilateral ligamenta reconstruction at our hospital;\n\nExclusion Criteria:\n\n1. Be older than 40 years, or less than 18 years old\n2. Severe injury to other knee ligaments\n3. History of knee trauma","45 Years",{"count":322,"type":22},60,[25],"To explore the effect of preoperative exercise rehabilitation on bone mineral density, tendon bone healing, change of cartilage, and gait feature in patients with anterior cruciate ligament rupture.",[326],"Anterior Cruciate Ligament Rupture","2026-04-12",{"date":329,"type":37},"2026-04-15",{"date":331,"type":37},"2023-07-10",{"date":206,"type":22},{"name":43,"class":44},{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":340,"targetDuration":192,"studyType":58,"phases":4,"briefSummary":342,"conditions":343,"keywords":346,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":45},"100633880","a-bidirectional-cohort-study-on-prophylactic-resection-surgery-in-populations-at-moderate-to-high-risk-for-hereditary-ovarian-cancer-100633880","NCT07532434","A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer","Inclusion Criteria:\n\n* Gender: Female. Age: 18 years or older at the time of enrollment.Genetic Risk: Documented carriers of pathogenic or likely pathogenic germline mutations in high-risk ovarian cancer susceptibility genes (including BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2). Data Availability: Willing to provide informed consent and allow access to clinical records, genetic testing reports, and follow-up data (bidirectional cohort). Psychosocial Status: Ability to complete quality of life and psychological assessment scales (e.g., GCS, SF-36, FSFI).\n\nExclusion Criteria:\n\n* Prior Malignancy: History of ovarian, fallopian tube, or primary peritoneal cancer prior to the baseline intervention. Synchronous Malignancy: Diagnosis of any other advanced-stage malignancy. Inability to Follow-up: Significant psychological, social, or geographical factors that would prevent regular long-term follow-up (3 years). Previous Extensive Pelvic Surgery: History of extensive pelvic surgery that precludes the feasibility of laparoscopic prophylactic salpingectomy or oophorectomy.",{"count":341,"type":22},480,"The goal of this multi-center observational study is to learn about the effectiveness and safety of different prophylactic (preventive) surgical options in women at moderate-to-high genetic risk for hereditary ovarian cancer (HOC).\n\nThe main questions it aims to answer are:\n\nDoes individualized prophylactic surgery (such as removing fallopian tubes now and delaying ovary removal) effectively reduce the risk of developing ovarian cancer compared to standard care or close monitoring?\n\nHow do these different surgical interventions affect a woman's ovarian function and quality of life?\n\nWhat Participants Will Do:\n\nParticipants who are healthy carriers of specific genetic mutations (such as BRCA1\u002F2, RAD51C\u002FD, etc.) will be followed in a bidirectional cohort. Depending on the medical care and surgical path they choose with their doctors (Standard RRSO, Delayed Oophorectomy, or Close Monitoring), researchers will collect their clinical data, surgical pathology results, and follow-up information regarding cancer incidence and quality of life for 3 years.",[344,345],"Ovarian Cancer","Breast Cancer",[347,348,349,350,351],"Hereditary Ovarian Cancer (HOC)","BRCA1\u002F2 Mutation Carriers","Risk-Reducing Salpingo-Oophorectomy (RRSO)","Bidirectional Cohort Study","Risk-Reducing Salpingo-Oophorectomy（RRSO）","2026-04-08",{"date":329,"type":37},{"date":355,"type":37},"2025-09-30",{"date":357,"type":22},"2035-09-30",{"name":43,"class":44},{"id":360,"slug":361,"hasResults":12,"nctId":362,"briefTitle":363,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":320,"enrollmentInfo":365,"targetDuration":4,"studyType":23,"phases":367,"briefSummary":368,"conditions":369,"keywords":371,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":380},"100625525","effects-of-a-preoperative-cognitive-behavioral-intervention-on-kinesiophobia-and-function-in-anterior-cruciate-ligament-reconstruction-100625525","NCT07423767","Effects of a Preoperative Cognitive-Behavioral Intervention on Kinesiophobia and Function in Anterior Cruciate Ligament Reconstruction","Inclusion Criteria:\n\n1. Patients aged 18 to 45 years with a diagnosis of anterior cruciate ligament (ACL) rupture.\n2. ACL rupture within 3 months prior to enrollment.\n3. First-time ACL rupture with a scheduled reconstruction surgery at this institution.\n4. The affected knee shows no significant redness, swelling, pain, or inflammation, with basic activities of daily living restored.\n5. No injury or only mild (grade I) injury to the posterior cruciate ligament, medial collateral ligament, or lateral collateral ligament.\n\nExclusion Criteria:\n\n1. Body mass index (BMI) less than 18.5 or greater than 35 kg\u002Fm².\n2. Age older than 45 years or younger than 18 years.\n3. ACL rupture with a duration exceeding 3 months.\n4. Concurrent severe injury (greater than grade I sprain) to the posterior cruciate ligament, medial collateral ligament, or lateral collateral ligament. (Note: Grade II indicates partial tear with ligament thickening, laxity, and partial fiber disruption; Grade III indicates complete rupture).\n5. Concurrent severe meniscal tear.\n6. History of prior knee surgery (e.g., meniscal repair, ligament reconstruction, joint replacement, arthroscopic debridement).\n7. Presence of other significant knee pathologies, such as: knee osteoarthritis, knee tumor, rheumatoid arthritis, tuberculosis, or active infectious\u002Finflammatory diseases of the knee.\n8. Concurrent fracture, dislocation, or other osseous injuries involving the knee.\n9. Unwillingness to receive the treatment protocol of this study.",{"count":366,"type":22},44,[25],"This study aims to systematically elucidate the integrative effects of psychological rehabilitation on the \"brain-psychology-motor\" triad in patients with anterior cruciate ligament (ACL) rupture. We plan to recruit 44 patients (aged 18-45) diagnosed with ACL rupture and scheduled for reconstruction surgery at Peking University Third Hospital, who will be randomly assigned to two groups. Through synchronous acquisition of questionnaire scores, motor performance data (gait, jogging, postural stability), and central neural activity (EEG), this research seeks to establish a foundation for developing neuroscience evidence-based, precision rehabilitation strategies.",[370],"Anterior Cruciate Ligament (ACL) Tear",[372],"Anterior cruciate ligament; Cognitive-Behavioral Intervention",{"date":374,"type":37},"2026-04-13",{"date":376,"type":37},"2026-02-14",{"date":378,"type":22},"2027-08-01",{"name":43,"class":44},2,{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":54,"enrollmentInfo":389,"targetDuration":391,"studyType":58,"phases":4,"briefSummary":392,"conditions":393,"keywords":401,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":411,"locationsCount":45},"100601955","validation-of-rcc-predicting-model-with-emulated-target-trial-100601955","NCT07117227","Validation of RCC Predicting Model With Emulated-target Trial","Emulated-target Trial for Guiding Stratified Treatment for Renal Cell Carcinoma With Venous Tumor Thrombus","RCCETT","Inclusion Criteria:\n\n* Adults ≥18 years of age;\n* Diagnosis of primary renal cell carcinoma before and during the surgery;\n* Received radical nephrectomy\u002Fnephron-sparing surgery.\n\nExclusion Criteria:\n\n* Subjects with severely missing clinical information;\n* History of other malignant tumors.\n* Recurrence observed before first postoperative follow-up.\n* Discontinue the adjuvant treatment within in the first two course because of severe adverse react.",{"count":390,"type":22},4700,"2 Years","This single-center study utilizes real-world data (2012-2024) from 4700 renal cell carcinoma (RCC) patients at Peking University Third Hospital to: (1) Develop and validate a prognostic prediction model specifically for RCC patients, including those with venous tumor thrombus (VTT); (2) Compare the performance of this new model against existing RCC prediction models in both the overall RCC cohort and the VTT subgroup; (3) Employ an emulated target trial (ETT) methodology to evaluate whether risk-stratified treatment based on the prediction model (grouping patients as high\u002Fmedium\u002Flow risk) improves survival outcomes .",[394,395,396,397,398,399,400],"Renal Cell Carcinoma (Kidney Cancer)","Renal Cell Carcinoma (RCC)","Tumor Thrombus","Prognosis","Prognostic Cancer Model","Real World Study","Observational Study",[402,403,404,405],"renal cell carcinoma","tumor thrombus","prognostic model","emulated-target trial",{"date":407,"type":37},"2026-04-14",{"date":409,"type":37},"2025-09-01",{"date":378,"type":22},{"name":43,"class":44},{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":427,"leadSponsor":428,"locationsCount":45},"100602662","prospective-cohort-study-on-refractory-rheumatoid-arthritis-100602662","NCT07126431","Prospective Cohort Study on Refractory Rheumatoid Arthritis","Inclusion Criteria:\n\n1. Meet the 1987 American College of Rheumatology (ACR) classification criteria for RA or the 2010 ACR\u002FEuropean Alliance of Associations for Rheumatology (EULAR) classification criteria for RA.\n2. Age \\>18 years.\n3. Treatment with conventional synthetic DMARDs (csDMARDs) for at least 1 year.\n4. Fulfill the EULAR definition of difficult-to-treat RA (refractory RA).\n5. Provide written informed consent.\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years.\n2. Duration of DMARD therapy \\\u003C1 year.\n3. Patients unwilling to participate in the cohort study.",{"count":419,"type":22},200,"Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic erosive arthritis. Without timely and appropriate treatment, it can lead to joint destruction and disability. Current RA management emphasizes early diagnosis, early treatment, and a treat-to-target (T2T) approach to achieve disease remission as soon as possible.\n\nIn recent years, significant progress has been made in RA pharmacotherapy. With the clinical application of biologic disease-modifying antirheumatic drugs (bDMARDs) targeting cytokines and targeted synthetic DMARDs (tsDMARDs), treatment outcomes and prognosis have greatly improved. However, even with bDMARDs or tsDMARDs, some patients show poor response, maintaining moderate-to-high disease activity-a condition termed \"refractory RA\". Refractory RA has garnered increasing clinical attention, prompting the European Alliance of Associations for Rheumatology (EULAR) to establish a standardized definition and diagnostic criteria in 2020 to facilitate research.\n\nCurrently, effective treatments for refractory RA are lacking. These patients often present with extra-articular manifestations and comorbidities, posing significant therapeutic challenges. They exhibit higher rates of bone destruction and joint deformities, severely impairing work capacity and quality of life, thereby imposing heavy burdens on families and society.\n\nStudies from Western countries estimate refractory RA prevalence at 5-20%, while its exact incidence in China remains unknown. Given regional disparities in rheumatology care and low overall RA remission rates in China, the proportion of refractory RA may be higher. Historically, this patient population has been understudied, and no prospective refractory RA cohort has been established in China.\n\nKey factors contributing to refractory RA in China-including clinical phenotypes, immune subtypes, and predictive biomarkers-remain unclear. Developing personalized treatment strategies to manage refractory RA requires further exploration. There is an urgent need for prospective cohort studies to address these gaps.\n\nThis project aims to establish a dedicated refractory RA cohort to investigate its clinical and immune phenotypes under current T2T strategies and expanded bDMARD\u002FtsDMARD insurance coverage. The investigators will explore potential clinical predictors and biomarkers, implement personalized therapies, and evaluate treatment efficacy, remission rates, and the predictive value of different phenotypes\u002Fsubtypes. Additionally, the investigators will assess impacts on patient-reported outcomes (PROs) and quality of life. The findings will provide critical insights into refractory RA pathogenesis, predictive markers, and tailored therapeutic approaches.",[422],"Rheumatoid Arthritis","2026-03-29",{"date":425,"type":37},"2026-04-02",{"date":70,"type":37},{"date":41,"type":22},{"name":43,"class":44},{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":79,"sex":53,"minAge":18,"maxAge":54,"enrollmentInfo":436,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":437,"conditions":438,"keywords":442,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":4},"100629100","detection-of-diabetic-foot-skin-damage-using-plantar-mechanical-parameters-100629100","NCT07470255","Detection of Diabetic Foot Skin Damage Using Plantar Mechanical Parameters","An Exploratory Study on the Detection of Diabetic Foot Skin Damage Using Quantitative Mechanical Parameters of Plantar Skin","Inclusion Criteria:\n\n* For healthy one: Fasting blood glucose \\\u003C 6.1 mmol\u002FL and glycated hemoglobin \\\u003C 6.0%, with no history of diabetes; Foot condition: normal appearance of both feet, without wounds, deformities, trauma, infections, or dermatological disorders; voluntary participation in this study with signed informed consent.\n* For diabetic one: Confirmation of type 1 or type 2 diabetes mellitus as defined by the World Health Organization (WHO) diagnostic standards; Diagnosis of diabetic foot disease\\* consistent with the criteria established by the International Working Group on the Diabetic Foot (IWGDF); Voluntary participation in the present study with provision of signed informed consent.\n\nExclusion Criteria:\n\n* For healthy one: (1) History of foot surgery, trauma, or fractures resulting in skin scars or irreversible cutaneous damage; (2) Active chronic dermatological conditions affecting skin integrity, such as tinea pedis, eczema, or psoriasis; (3) Vascular diseases of the lower extremities (e.g., arteriosclerosis obliterans) causing muscular or cutaneous atrophy in the feet; (4) Systemic diseases impacting the skin or connective tissues, including systemic sclerosis, rheumatoid arthritis, or vasculitis; (5) Prolonged engagement in heavy physical labor or professional sports leading to abnormal thickening or hyperkeratosis of the plantar skin; (6) Presence of extensive, hyperkeratotic lesions (e.g., calluses, corns) or wounds at the measurement site impairing probe contact accuracy; (7) Inability to cooperate or diagnosed psychiatric disorders; (8) Investigator-determined unsuitability for the study or inability to comply with protocol requirements.\n* For diabetic one: (1) Uncontrolled severe acute foot infections; (2) Dermatological conditions that interfere with measurement procedures; (3) Irreversible foot skin damage due to non-diabetic etiologies such as trauma or surgical intervention; (4) Coexisting systemic disorders (excluding diabetes) that compromise skin elasticity, including systemic sclerosis, rheumatoid arthritis, or vasculitis; (5) History of above-knee amputation on the measured foot; (6) Inability to cooperate or presence of psychiatric disorders; (7) Investigator-determined ineligibility due to non-compliance concerns or unsuitability for study participation.",{"count":419,"type":22},"Diabetes represents one of the major chronic diseases, with diabetic ulcers being a significant adverse prognosis. Approximately 80% of lower limb amputations are attributed to diabetic foot ulcers, which constitute a primary cause of patient disability and mortality, while also imposing a substantial burden on healthcare systems. Although standardized Western medical protocols for diabetic foot management exist, clinical outcomes remain suboptimal. The amputation rate due to diabetic foot ulcers continues to rise annually, underscoring the urgent need for novel and effective interventions to address this condition.\n\nQuantitative assessment of cutaneous biomechanical parameters may indirectly reflect the cumulative damage inflicted by diabetes on foot tissues. Such evaluation provides critical guidance for predicting susceptibility to recurrent ulceration and determining the necessity of enhanced offloading strategies to prevent ulcer development. By applying specific mechanical loads to the skin and measuring deformation, rebound characteristics, and displacement dynamics under pressure, it becomes possible to quantitatively evaluate parameters such as elastic modulus and viscoelastic properties.\n\nThis case-control study aims to investigate the feasibility of utilizing plantar skin quantitative mechanical parameters as objective biomarkers for biomechanical impairment in diabetic foot. Furthermore, it seeks to establish a standardized operating procedure (SOP) for quantitative measurements tailored to diabetic foot scenarios. The study is designed to bridge critical evidence gaps between theoretical consensus and clinically applicable quantitative tools, demonstrating clear innovation and potential clinical value.",[439,440,441],"Diabetic Foot Disease","Diabete Mellitus","Mechanical Factor",[439,440,443,444],"Mechanical factor","plantar skin","2026-03-12",{"date":447,"type":37},"2026-03-13",{"date":449,"type":22},"2026-04-01",{"date":451,"type":22},"2028-04-01",{"name":43,"class":44},{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":461,"targetDuration":4,"studyType":23,"phases":463,"briefSummary":464,"conditions":465,"keywords":467,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":4},"100627933","a-single-center-dose-escalation-clinical-study-to-evaluate-the-safety-tolerability-and-preliminary-efficacy-of-tumor-neoantigen-pulsed-autologous-dendritic-cell-injection-ys247-in-study-participants-with-hrd-negative-epithelial-ovarian-cancer-100627933","NCT07455071","A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer","An Investigator Initiated Clinical Study of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in the Treatment of Patients With HRD-negative Epithelial Ovarian Cancer","YS247","Inclusion Criteria:\n\n1. Female aged 18-70 years (inclusive of cut-off values); body weight ≥45 kg.\n2. Failed to achieve Complete Response (CR) after completion of at least first-line therapy (i.e., surgery and platinum-based chemotherapy), with abnormal CA125 levels or at least one measurable lesion confirmed by imaging assessment.\n3. Completed genomic and transcriptomic sequencing of tumor samples, finished the analysis of genetic mutation characteristics and immune characteristics of tumor samples, and is eligible for screening of personalized tumor neoantigens.\n4. Laboratory examinations must meet the following criteria: white blood cell count ≥4.0×10⁹\u002FL; absolute lymphocyte count ≥1.0×10⁹\u002FL; platelet count ≥80×10⁹\u002FL; hemoglobin ≥9.0 g\u002FL; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×Upper Limit of Normal (ULN) (≤5×ULN for patients with concurrent liver metastases); bilirubin ≤1.5×ULN (≤3×ULN for patients with Gilbert's syndrome); alkaline phosphatase (ALP) ≤2.5×ULN (≤5×ULN for patients with concurrent liver metastases); albumin ≥30 g\u002FL; serum creatinine and\u002For urea \\\u003C1.5 times the normal value; coagulation tests: international normalized ratio (INR) \\\u003C1.7 or prolonged prothrombin time (PT) \\\u003C4 seconds.\n5. 12-lead electrocardiogram (ECG) must meet the following criteria: no severe arrhythmia, QTcF ≤480 ms.\n6. Toxic and adverse reactions induced by previous treatments must have recovered to Grade ≤1 (per NCI-CTCAE v5.0), with the exception of stable Grade 2 sensory neuropathy or alopecia (per CTCAE).\n7. With patent vascular access and capable of undergoing peripheral blood mononuclear cell (PBMC) collection.\n8. Expected survival time \\>6 months.\n9. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-1 (see Appendix 2).\n10. Fertile study participants must agree to adopt medically effective contraceptive measures throughout the trial period and for at least 6 months after the last administration; fertile study participants must have a negative pregnancy test result within 28 days prior to enrollment and at baseline.\n11. Study participants are able to understand the trial procedures, are willing to comply with the clinical trial protocol to complete the trial, and have signed the informed consent form (ICF).\n\nExclusion Criteria:\n\n1. (Per interview) Allergic diathesis with hypersensitivity to two or more drugs, or known hypersensitivity to any component of the personalized neoantigen-sensitized autologous dendritic cell injection (cell cryopreservation solution CS10, human albumin, 0.9% sodium chloride injection).\n2. (Per interview) A past or current diagnosis of Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML).\n3. (Per interview) Patients with symptomatic, uncontrolled brain metastasis or leptomeningeal metastasis.\n4. (Per interview) Suffering from severe or uncontrolled diseases, including but not limited to: uncontrolled ventricular arrhythmia, myocardial infarction within the recent 3 months, uncontrolled grand mal epilepsy, unstable spinal cord compression, superior vena cava syndrome, immunodeficiency (excluding splenectomy), or other diseases that the investigator deems may expose the patient to a high risk of harm.\n5. Positive for Human Immunodeficiency Virus (HIV) antibody, Treponema Pallidum (TP) antibody, or Hepatitis C Virus (HCV) antibody; or evidence of active hepatitis B via Hepatitis B Virus (HBV) surface antigen\u002FHBV DNA testing.\n6. New York Heart Association (NYHA) Grade III-IV congestive heart failure, or clinically significant arrhythmia with poor control.\n7. Uncontrolled arterial hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg).\n8. (Per interview) A history of or current comorbidities including the following:a) Autoimmune disease requiring long-term (more than 2 months) systemic immunosuppressant (corticosteroid) therapy, or immune-mediated symptomatic diseases (including ulcerative colitis, Crohn's disease, rheumatoid arthritis, Systemic Lupus Erythematosus (SLE), autoimmune vasculitis (e.g., Wegener's granulomatosis));b) A past diagnosis of immune-mediated motor neuron disease;c) A past diagnosis of Toxic Epidermal Necrolysis (TEN);d) Any psychiatric disorder (including dementia, altered mental status) that may impair the understanding and completion of informed consent and relevant questionnaires;e) Long-term use of non-inhaled corticosteroids, hydroxyurea, or immunomodulatory drugs;f) A history of other active malignant tumors within the past 5 years (excluding patients with basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the breast that have been completely cured and require no follow-up treatment);g) Hypothyroidism (patients with hypothyroidism requiring only thyroid hormone replacement therapy are eligible for enrollment).\n9. (Per interview) Judged by the investigator as unsuitable for enrollment or unable to comply with the protocol requirements, including but not limited to: persistent fever (\\>24 h) documented by repeated measurements or due to active, uncontrolled infection from screening to prior to drug administration.\n10. (Per interview) Receipt of cellular immunotherapy within the past 6 months (including: Cytokine-Induced Killer (CIK) cells, dendritic cell (DC) therapy, DC-CIK therapy, Lymphokine-Activated Killer (LAK) cells, and other cellular immunotherapies).\n\n    In addition to the above requirements, patients who meet any of the following criteria shall also be excluded prior to the collection of autologous peripheral blood mononuclear cells (PBMCs):\n11. Receipt of platelet or red blood cell transfusion within 3 weeks prior to collection.\n12. Receipt of chemotherapy within 3 weeks prior to collection.\n13. Receipt of anti-angiogenic tyrosine kinase inhibitor (TKI) small-molecule drugs within 3 weeks prior to collection.\n14. Use of corticosteroids (or analogs) or systemic administration of immunomodulatory therapies within 3 weeks prior to collection.\n15. Participation in a clinical study of an investigational non-biolgical product (administered within the past 30 days or 5 half-lives, whichever is longer) or an investigational biological product (monoclonal or polyclonal antibodies) (administered within the past 4 months or 5 half-lives, whichever is longer) prior to screening.\n16. Pregnant or lactating female study participants.\n17. Study participants with insufficient sensitivity to immunotherapy as determined by tumor genetic analysis.\n18. Study participants who are judged by the investigator as unable to adhere to the trial procedures, or deemed ineligible for enrollment for any other reason.",{"count":462,"type":22},9,[25],"This is a single-center, open-label, dose-escalation, multiple-dose investigator-initiated exploratory study designed to evaluate the safety, tolerability and preliminary efficacy of tumor neoantigen-pulsed autologous dendritic cell injection (YS247) in participants with HRD-negative epithelial ovarian cancer.",[466],"HRD-negative Epithelial Ovarian Cancer",[468,469,470,471],"tumor neoantigen","autologous dentritic cell","HRD-negative epithelial ovarian cancer","ovarian cancer",{"date":473,"type":37},"2026-03-16",{"date":475,"type":22},"2026-03-01",{"date":477,"type":22},"2027-11-30",{"name":43,"class":44},{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":23,"phases":487,"briefSummary":488,"conditions":489,"keywords":491,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":45},"100624634","research-and-clinical-validation-of-a-wearable-device-based-remote-rehabilitation-system-for-postoperative-rotator-cuff-injury-100624634","NCT07412184","Research and Clinical Validation of a Wearable Device-Based Remote Rehabilitation System for Postoperative Rotator Cuff Injury","Inclusion Criteria:\n\n* Age ≥18 years;\n* First-time rotator cuff injury surgery and received surgical treatment at Peking University Third Hospital;\n* MRI shows a tear with a maximum diameter \\\u003C3 cm, confirmed by at least three musculoskeletal rehabilitation radiologists;\n* Possess a mobile device with internet access (e.g., smartphone or tablet) capable of using mobile applications;\n* Able to complete the planned study and follow-ups within 6 months after discharge;\n* No visual, hearing, cognitive, or communication impairments;\n* Able to provide informed and valid consent to participate in the study.\n\nExclusion Criteria:\n\n* Presence of serious cardiovascular or cerebrovascular diseases, or cervical spondylosis with nerve damage;\n* Presence of cognitive impairment or vision problems;\n* Stroke, rheumatic disease, neurological disorders, or diseases limiting overall physical function or cardiopulmonary function within the past 2 years;\n* No prior history of shoulder joint injury, and having undergone other surgeries within the past 6 months;\n* Patients who cannot complete the entire cycle or drop out midway;\n* Presence of serious postoperative complications, such as wound infection, venous thromboembolism, etc.",{"count":486,"type":22},72,[25],"This study included patients who underwent their first shoulder rotator cuff surgery at Peking University Third Hospital, diagnosed with small to medium rotator cuff tears based on MRI results. Participants were randomly divided into an online wearable device training group and an offline traditional rehabilitation group, with 36 individuals in each group. Before testing began, patients were ensured to participate voluntarily and had signed informed consent forms.",[490],"Rotator Cuff Tear",[492,493,494],"Rotator cuff tear","Wearable device","Remote rehabilitation","2026-03-08",{"date":497,"type":37},"2026-03-10",{"date":499,"type":37},"2026-01-23",{"date":501,"type":22},"2027-12-31",{"name":43,"class":44},{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":54,"enrollmentInfo":510,"targetDuration":4,"studyType":23,"phases":512,"briefSummary":513,"conditions":514,"keywords":517,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":45},"100628340","phase-2-glofitamab-combined-with-lenalidomide-in-high-risk-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-100628340","NCT07460362","Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma","A Single-arm, Open-label, Multi-center Clinical Study of Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With a BTK Inhibitor","Inclusion Criteria:\n\n* • Signed Informed Consent Forms\n\n  * Age: \\>= 18 to 80 years\n  * Eastern Cooperative Oncology Group =\\\u003C 2\n  * Diagnosis of MCL established by histologic assessment\n  * Previously treated with at least one prior line of systemic therapy for mantle cell lymphoma.\n  * Prior therapy have included a BTK inhibitor, including ibrutinib, zanubrutinib, obrutinib, acalabrutinib and various BTKi in clinical trials. BTki exposure is required, which include BTKi failure or intolerance. BTKi failure is defined as progression of disease during BTKi therapy or patients have progressed or relapsed after completing BTK inhibitor therapy\n  * At least one high risk features as classified:\n\n    * Blastoid\u002Fpleomorphic variants ✔ Ki67 ≥50% ✔ TP53 mutation or deletion\n    * Bulky disease (defined as any lesion ≥7.5 cm on the screening computed tomography \\[CT\\] scan）\n    * Patients that did not achieve a CR with their first-line treatment\n    * early disease progression (POD24) ✔ patients with relapse and refractory treatment above 3 lines\n  * Measurable lesions on cross-sectional imaging documented by diagnostic imaging(MRI, CT or PET-CT), （GTD）≥1.5 cm\n  * Adequate liver function : Total bilirubin =\\\u003C 3 x upper limit of normal (ULN) (unless has Gilbert's disease), Aspartate aminotransferase (AST) =\\\u003C 5.0 x ULN, Alanine aminotransferase (ALT) =\\\u003C 5.0 x ULN\n\nExclusion Criteria:\n\n* • Already enrolled in other Ongoing interventional or non-interventional R\u002FR MCL clinical trials;\n\n  * Currently receiving immunosuppressive treatment for other diseases;\n  * Previous treatment with lenalidomide;\n  * Combined with other malignant tumors within 3 years;\n  * The researcher determines that they are not suitable to participate in this study;\n  * Serious mental or neurological disorders that affect informed consent and\u002For the expression or observation of adverse reactions;\n  * Have a history of major or extensive cardiovascular disease, such as New York Heart Association class III or Grade IV heart disease or objective assessment, myocardial infarction, unstable arrhythmia or unstable angina within 6 months before the first cycle;\n  * Recent major surgery (within 4 weeks before the start of the first cycle);\n  * Active autoimmune diseases with poor treatment control;\n  * Any active infection that may affect the safety of the participant, including bacterial, fungal and various viral infections, occurred within 7 days before the first day of cycle 1;\n  * Positive SARS-CoV-2 PCR test within 7 days prior to enrollment\n  * Positive test results for chronic hepatitis B infection (defined as positive hepatitis B surface antigen \\[HBsAg\\] serology) Participants with occult or prior hepatitis B infection (defined as positive total hepatitis B core antibody and negative HBsAg) may be included if hepatitis B virus (HBV) DNA is undetectable at the time of screening. Such participants must be willing to undergo HBV DNA testing on Day 1 of every cycle and every 3 months for at least 12 months after the final cycle of study treatment and appropriate antiviral therapy as indicated.\n  * Positive test results for hepatitis C (hepatitis C virus \\[HCV\\] antibody serology testing) Participants positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.\n  * A history of severe deep vein thrombosis event or pulmonary embolism within 6 months\n  * Patient follow-up was not possible.",{"count":511,"type":22},43,[142],"A single-arm, open-label, multi-center clinical study of glofitamab combined with lenalidomide in high risk patients with relapsed or refractory Mantle Cell Lymphoma previously treated with a BTK Inhibitor.\n\nPatients will be eligible if they have received one or more prior lines of therapy, one of which must have been a BTKi. Patients will be enrolled according to a Simon two-stage design, with early stop criteria for lack of efficacy.\n\nGlofitamab will be administered intravenously and lenalidomide will be self-administered orally.\n\nObinutuzumab pretreatment will be administered intravenously as 2 doses of 1000 mg prior to glofitamab initiation. The primary endpoint is BOR at the end of induction, evaluated by PET\u002FCT according to Lugano criteria during study enrolment.\n\nThe primary objective is to evaluate the best objective response rate (BOR) at the end of induction of the combination of glofitamab and lenalidomide.",[515,516],"MCL","Relapsed or Refractory Mantle Cell Lymphoma (MCL)",[518],"Relapsed or Refractory MCL, previously treated with a BTK Inhibitor","2026-03-05",{"date":497,"type":37},{"date":522,"type":37},"2025-08-11",{"date":524,"type":22},"2029-12-30",{"name":43,"class":44},{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":532,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":534,"conditions":535,"keywords":537,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":549,"locationsCount":550},"100627803","multisensor-wireless-pressure-microcatheter-for-microvascular-function-assessment-in-anocainoca-patients-a-prospective-multicenter-single-group-target-value-study-100627803","NCT07453381","Multisensor Wireless Pressure Microcatheter For Microvascular Function Assessment In ANOCA\u002FINOCA Patients: A Prospective, Multicenter, Single-Group Target Value Study","Inclusion Criteria:\n\n1. Age ≥ 18 years, gender not limited;\n2. Symptoms of angina pectoris, or objective evidence of myocardial ischemia (e.g., electrocardiogram, myocardial injury markers, etc.);\n3. Visual assessment of coronary angiography shows diameter stenosis \\\u003C 50% and FFR \\> 0.8 (or cRR \\> 0.89);\n4. Microvascular function assessment is planned;\n5. Agree to participate in this clinical study and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n1. Acute myocardial infarction, PCI, CABG, or valvular surgery following angiography within the past 30 days;\n2. Severe valvular disease requiring surgical or interventional treatment;\n3. Chest pain with known non-ischemic causes (e.g., pericarditis, pulmonary hypertension, esophageal spasm);\n4. Contraindications to CMR (e.g., certain types of pacemakers or defibrillators, severe claustrophobia);\n5. Clear contraindications to adenosine and ATP use (e.g., second- or third-degree atrioventricular block, sick sinus syndrome, severe asthma, systolic blood pressure below 90 mmHg);\n6. Renal insufficiency (eGFR ≤ 45 mL\u002Fmin\u002F1.73 m2) or currently undergoing dialysis;\n7. Severe heart failure or LVEF ≤ 35%;\n8. Severe organ disease or life expectancy less than 2 years;\n9. Known to be participating in other drug or device clinical trials that have not yet met the primary endpoint;\n10. Other investigators deem the candidate unsuitable for this clinical trial.",{"count":533,"type":22},114,"This study aims to evaluate the sensitivity and specificity of a multi-sensor wireless pressure microcatheter for the diagnosis of CMD in patients with ANOCA\u002FINOCA, using quantitative myocardial perfusion imaging of cardiac magnetic resonance (CMR) as a reference.",[536],"Coronary Microvascular Dysfunction (CMD)",[538,539,540,541,542],"Pressure Microcatheter","Microvascular Function Assessment","Angina with Non-obstructive Coronary Arteries","Ischaemia with Non-obstructive Coronary Arteries","Coronary Microvascular Dysfunction",{"date":544,"type":37},"2026-03-06",{"date":546,"type":22},"2026-03-23",{"date":548,"type":22},"2026-10-31",{"name":43,"class":44},3,{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":557,"enrollmentInfo":558,"targetDuration":4,"studyType":23,"phases":560,"briefSummary":561,"conditions":562,"keywords":564,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":568,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":4},"100627699","construction-of-a-comprehensive-health-management-platform-for-patients-with-cardiovascular-kidney-metabolic-syndrome-100627699","NCT07452029","Construction of a Comprehensive Health Management Platform for Patients With Cardiovascular-Kidney-Metabolic Syndrome","Inclusion Criteria:\n\n* CKM stage 0-2 as defined by the American Heart Association CKM diagnostic guidelines\n* Age 18-75 years\n* Able to use a smartphone and wearable activity tracker\n* Willing to sign informed consent and attend scheduled follow-up visits\n\nExclusion Criteria:\n\n* CKM stage 3-4\n* Acute or critically ill conditions requiring hospitalization\n* Malignant tumors or any active cancer under treatment","75 Years",{"count":559,"type":22},150,[25],"Cardiovascular-Kidney-Metabolic (CKM) syndrome underscores the pathophysiologic interplay among metabolic risk factors, chronic kidney disease (CKD) and the cardiovascular system. This crosstalk precipitates multi-organ dysfunction, increases adverse cardiovascular events, and imposes heavy familial and socioeconomic burdens. Building a health-management platform within research wards is therefore urgent. Such a platform is the pivotal venue for assessment, monitoring, intervention and follow-up in continuous care.\n\nLeveraging the existing health-management system of the Health Screening Center at Peking University Third Hospital, the investigators will develop a comprehensive CKM platform that integrates systemic inflammatory biomarkers, cardiovascular early-warning algorithms, and personalized diet-and-exercise prescriptions. The system will provide cyclic management encompassing evaluation, guidance, monitoring, feedback and longitudinal follow-up.\n\nA randomized controlled trial with two-year prospective follow-up will enroll patients at CKM stages 0-2 to evaluate clinical improvement, quality of life, dietary behavior and physical activity after platform enrollment. The project will enable early identification of high-risk individuals, deliver precision management, maximize data utility, and offer a novel research-ward model that addresses mobile-health pain points and closes the CKM care loop.",[563],"Cardiovascular-Kidney-Metabolic Syndrome",[565,566,567,563],"Comprehensive Health Management Platform","Mobile Health","Early identification",{"date":519,"type":37},{"date":570,"type":22},"2026-03",{"date":572,"type":22},"2027-12",{"name":43,"class":44},{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":4,"eligibilityCriteria":580,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":581,"targetDuration":582,"studyType":58,"phases":4,"briefSummary":583,"conditions":584,"keywords":588,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":597,"locationsCount":45},"100627724","ai-based-diabetic-foot-recurrence-cohort-100627724","NCT07452354","AI-Based Diabetic Foot Recurrence Cohort","Development and Validation of an AI-Based Wound Alert System With a Home-Based Management Model for a Diabetic Foot Recurrence Cohort","Inclusion Criteria:\n\n* The patient must be aged 18 years or older; have a confirmed diagnosis of type 1 or type 2 diabetes mellitus according to the World Health Organization criteria; the wound etiology attributable to diabetic foot ulcers, with complete wound healing post-treatment defined as a dry wound devoid of exudate, complete epithelialization of both the wound bed and margins, absence of surrounding erythema or edema, and sufficient tensile strength to withstand pressure without dehiscence; voluntary participation in this study with provision of written informed consent.\n\nExclusion Criteria:\n\n* Inability of the patient to cooperate or presence of psychiatric disorders; At the investigator's discretion, the subject is deemed unsuitable for this study or unable to comply with the study requirements.",{"count":419,"type":22},"3 Months","Diabetic foot ulcer (DFU) is a major adverse outcome of diabetes, which itself is one of the most significant chronic diseases. The recurrence of DFU involves multiple risk factors, including altered foot loading patterns, patient compliance, family care capacity, blood glucose monitoring, degree of ischemia, and systemic disease control. Early identification of recurrence signs and timely follow-up interventions are crucial for improving prognosis, reducing disability rates, and lowering healthcare costs. However, traditional follow-up systems lack individualized strategies-such as risk stratification, inflexible follow-up intervals, and insufficient compliance management-often resulting in suboptimal outcomes. High-risk patients prone to recurrence may not be followed up frequently enough for early detection, while low-risk patients may undergo unnecessary visits, increasing burdens on both patients and healthcare providers. This inefficiency contributes significantly to the persistently high rates of disability and mortality among recurrent DFU patients.\n\nEstablishing an individualized follow-up strategy for DFU, supported by advanced technology to address core bottlenecks such as delayed recurrence warnings and inadequate home-based management, represents an effective technical pathway to tackle these issues.\n\nOur center proposes to develop a dedicated DFU cohort with comprehensive active follow-up and a multimodal database encompassing well-defined indicators. We aim to explore a high-risk foot grading system for preventing DFU recurrence and design targeted follow-up protocols. By leveraging AI technology, we intend to build a wound warning system capable of identifying DFU recurrence. Furthermore, we seek to establish a telemedicine and AI-assisted, patient-centered home-based self-management framework for early warning and prevention of DFU recurrence.",[585,440,586,587],"Diabetic Foot Ulcer (DFU)","Diabetic Foot Ulcer Treatment","Artificial Intelligence (AI) in Diagnosis",[589,586,440,590,587],"Diabetic Foot Ulcer","Reccurrence","2026-02-28",{"date":519,"type":37},{"date":594,"type":22},"2026-03-15",{"date":596,"type":22},"2028-12-31",{"name":43,"class":44},{"id":599,"slug":600,"hasResults":12,"nctId":601,"briefTitle":602,"officialTitle":602,"acronym":4,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":54,"enrollmentInfo":604,"targetDuration":4,"studyType":23,"phases":606,"briefSummary":607,"conditions":608,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":612,"lastUpdatePostDateStruct":613,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":45},"100580740","randomized-controlled-trial-on-the-efficacy-and-safety-of-xiang-lei-ointment-in-diabetic-related-ulcer-management-100580740","NCT06841237","Randomized Controlled Trial on the Efficacy and Safety of Xiang Lei Ointment in Diabetic-related Ulcer Management","Inclusion Criteria:\n\n* a confirmed diagnosis of type 1 or type 2 diabetes mellitus that meets the standard World Health Organization definition, with blood glucose controlled prior to enrolment and a glycated haemoglobin HbA1c level of less than 10%;\n* the type of wound is an ulcer;\n* the wound etiology is diabetic, mainly abnormalities in blood glucose, resulting in poor or prolonged healing and requiring standard wound therapy;\n* the staging of the wound is in the granulation phase;\n* voluntary participation in the study and signing of an informed consent form.\n\nExclusion Criteria:\n\n* acute heart attack, heart failure, hepatitis, shock, expiratory failure and other serious diseases that have not been corrected;\n* uncontrolled blood glucose, fasting blood glucose \\> 15 mmol\u002FL and glycated haemoglobin \\> 12%;\n* active bleeding in the wound, which does not allow the implementation of the conventional basic treatment plan;\n* serum albumin \\< 20 g\u002FL; haemoglobin \\< 60 g\u002FL; platelets \\< 50 x 109\u002FL;\n* a state of disseminated infection that is being or will be treated with antibiotics\n* patients with advanced malignant tumours;\n* active autoimmune disease;\n* previous allergy to topical human granulocyte macrophage stimulating factor gel (Jinfuning);\n* inability of the patient to co-operate or mental disorder;\n* in the judgement of the investigator, the subject has a clearly irremovable cause of wound healing, is unsuitable for the study or is unable to comply with the requirements of the study.",{"count":605,"type":22},56,[25],"Diabetes is one of the major chronic diseases. Diabetic ulcers are important adverse outcomes of diabetes. Approximately 80% of lower - limb amputations are caused by diabetic foot ulcers, which are the main causes of disability and death among patients. Moreover, it places a huge burden on the medical insurance system. Currently, there are western medicine treatment guidelines for diabetic foot, yet the clinical efficacy is less than satisfactory. The amputation rate caused by diabetic foot ulcers continues to rise every year. There is an urgent clinical need for novel and effective intervention measures to address this disease.\n\nMacrophages are important cells involved in the inflammatory and proliferative phases of wounds, playing a crucial role in wound repair and reconstruction. Diabetes can cause wounds to remain in the pro - inflammatory stage continuously, leading to the aggregation of M1 macrophages and preventing their timely transformation into the pro - proliferative and repair stage. As a result, wounds exhibit persistent chronic inflammation and delayed tissue proliferation or remodeling.\n\nXianglei Tangzu Ointment is a natural medicine approved for marketing by the National Medical Products Administration in November 2023. Its ingredients include Pogostemon cablin extract and asiaticoside. Research shows that the plant components in Xianglei Tangzu Ointment can promote the transformation of M1 macrophages into M2 macrophages, thereby reducing the inflammatory response and accelerating the proliferative repair of diabetic wounds. It has achieved certain curative effects in the clinical treatment of promoting wound healing. In order to use Xianglei Tangzu Ointment more precisely, accumulate clinical evidence - based medicine evidence, and explore the effectiveness and safety of Xianglei Tangzu Ointment in treating diabetic ulcers under the guidance of the chronic wound staging theory, clinical evidence - based medicine evidence needs to be obtained.",[609,610,611],"Diabetic Wound","Wound Infection","Wound Heal","2026-02-26",{"date":614,"type":37},"2026-03-02",{"date":616,"type":37},"2025-04-10",{"date":618,"type":22},"2027-02-15",{"name":43,"class":44},{"id":621,"slug":622,"hasResults":12,"nctId":623,"briefTitle":624,"officialTitle":624,"acronym":625,"eligibilityCriteria":626,"healthyVolunteers":12,"sex":53,"minAge":627,"maxAge":168,"enrollmentInfo":628,"targetDuration":629,"studyType":58,"phases":4,"briefSummary":630,"conditions":631,"keywords":638,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":645,"lastUpdatePostDateStruct":646,"startDateStruct":648,"completionDateStruct":650,"leadSponsor":652,"locationsCount":4},"100626161","walking-function-outcomes-following-surgical-correction-with-rehabilitation-versus-physical-therapy-alone-in-charcot-marie-tooth-disease-a-bidirectional-cohort-study-100626161","NCT07432035","Walking Function Outcomes Following Surgical Correction With Rehabilitation Versus Physical Therapy Alone in Charcot-Marie-Tooth Disease: A Bidirectional Cohort Study","CMT-WALK","Inclusion Criteria:\n\n* Participants aged 12 years or older at the time of enrollment\n* Genetically or clinically confirmed CMT, based on established diagnostic criteria\n* Presence of foot deformity and\u002For gait impairment attributable to CMT, as determined by a treating clinician\n* Ability to ambulate at least 10 meters, with or without assistive devices\n* Medically eligible for either functional surgical intervention or structured physical therapy, as determined by the treating team\n* Willingness and ability to participate in longitudinal follow-up assessments\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Previous major foot or ankle surgery that substantially altered lower-limb biomechanics\n* Presence of non-CMT-related neurological disorders affecting gait (eg, stroke, Parkinson disease, multiple sclerosis)\n* Severe musculoskeletal conditions unrelated to CMT that limit walking ability (eg, advanced hip or knee osteoarthritis)\n* Active lower-limb infection, ulceration, or acute injury at the time of enrollment\n* Severe cognitive impairment or psychiatric condition precluding reliable participation\n* Medical contraindications to surgery or exercise-based rehabilitation, when relevant\n* Inability to complete baseline functional assessments or anticipated inability to complete follow-up","12 Years",{"count":419,"type":22},"5 Years","The goal of this study is to compare changes in walking ability in people with Charcot-Marie-Tooth disease (CMT) who receive two different treatment approaches for foot deformities that affect walking.\n\nCMT is an inherited nerve condition that can cause muscle weakness, loss of sensation, and foot deformities. These changes often make walking difficult and can reduce independence and quality of life. Treatment options commonly include physical therapy alone or surgery to correct foot alignment followed by rehabilitation. However, it is not clear whether one approach leads to better long-term walking outcomes.\n\nThe main question this study aims to answer is whether individuals who undergo functional foot surgery followed by rehabilitation experience different changes in walking ability over time compared with those who receive structured physical therapy alone.\n\nResearchers will compare walking performance between these two treatment groups over a period of up to two years. Walking ability will be evaluated using standardized walking tests and patient questionnaires.\n\nParticipants included in this study are individuals with CMT-related foot deformities that affect walking and who received either surgery followed by rehabilitation or physical therapy alone. Researchers will analyze changes in walking ability over time and determine how many participants achieve meaningful improvement.\n\nThe findings from this study may help clinicians and individuals with CMT better understand how different treatment strategies influence walking function over time.",[632,633,634,635,636,637],"Charcot Marie Tooth Disease (CMT)","Pes Cavovarus","Surgery","Exercise Training","Neuromuscular Diseases (NMD)","Gait Disorders",[639,640,641,642,643,644],"Charcot Marie Tooth disease","Walking performance","Functional surgery","Physical therapy","Gait impairment","Propensity score matching","2026-02-24",{"date":647,"type":37},"2026-02-25",{"date":649,"type":22},"2026-02-11",{"date":651,"type":22},"2028-02-10",{"name":43,"class":44},""]